Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Utilization of recombinant influenza viruses and modified vaccinia ankara virus (MVA) with genes that encode for the Toxoplasma gondii SAG1 and SAG2 surface proteins, as vaccines against toxoplasmosis

Utilization of recombinant influenza viruses and modified vaccinia ankara virus (MVA) with genes that encode for the Toxoplasma gondii SAG1 and SAG2 surface proteins, as vaccines against toxoplasmosis

US Patent 9937251 · Granted Apr 10, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Vaccine immunogens2025
Vaccine composition and immunization method2015
Vaccine composition and immunization method2014